Premium
Rapid identification of mutations in a multidrug efflux pump in Pseudomonas aeruginosa
Author(s) -
Jalal Shah,
Wretlind Gunnar,
Gotoh Naomasa,
Wretlind Bengt
Publication year - 1999
Publication title -
apmis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 88
eISSN - 1600-0463
pISSN - 0903-4641
DOI - 10.1111/j.1699-0463.1999.tb01516.x
Subject(s) - efflux , biology , pseudomonas aeruginosa , tetracycline , mutant , multiple drug resistance , microbiology and biotechnology , dna gyrase , genetics , gene , drug resistance , escherichia coli , bacteria , antibiotics
The gene mexR regulates negatively the expression of the MexA‐MexB‐OprM efflux pump in Pseudomonas aeruginosa , and mutations in mexR cause a multiple antibiotic resistance phenotype. Five hundred and forty resistant clones of P. aeruginosa PAO503 were isolated after selection for resistance to chloramphenicol or tetracycline. All isolates showed similar phenotypes and were resistant to tetracycline, chloramphenicol and norfloxacin. Nineteen randomly selected isolates were analyzed. Since mutational analysis by direct sequencing of all regions of interest in several strains is time‐consuming and expensive, a screening method, Non‐Isotopic RNase Cleavage Assay (NIRCA TM ), was applied to identify mutant genes so that they could be targeted for DNA sequencing. NIRCA is a simple but rapid method for mutational analysis and can be performed in 3–4 h. Results of NIRCA analysis were compared with DNA sequencing. Both NIRCA and DNA sequencing analysis showed mexR gene mutations in 11 of 19 isolates but no alterations in 8 strains. An immunoblot assay showed overexpression of OprN, a component of another multidrug efflux pump, MexE‐MexF‐OprN, in those eight isolates. Nucleotide sequencing of quinolone resistance‐determining regions of DNA gyrase (gyrA) or topoisomerase IV (parC) showed no alterations in any of the 19 mutants. The data indicate that two efflux pump systems, MexA‐MexB‐OprM and MexE‐MexF‐OprN, were involved in multidrug resistance including quinolones and that NIRCA is a sensitive method for screening mutations.